Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials - PubM
7 hours ago
- #Network meta-analysis
- #GLP-1 receptor agonists
- #Obesity
- Comparison of tirzepatide, liraglutide, and semaglutide for weight management in patients with obesity or overweight without type 2 diabetes.
- Tirzepatide (10 mg and 15 mg) showed statistically greater weight reduction compared to liraglutide and semaglutide.
- Improvements in cardiometabolic factors (e.g., triglycerides, blood pressure) were greater with tirzepatide vs. liraglutide and comparable to semaglutide.
- All three medications had similar safety profiles.
- Study based on a Bayesian network meta-analysis of six randomized controlled trials.
- Tirzepatide demonstrated consistent efficacy in weight loss and metabolic health compared to existing GLP-1 receptor agonists.